These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 8086668)
21. Topoisomerase I inhibitors. An overview of the camptothecin analogs. Burris HA; Fields SM Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144 [TBL] [Abstract][Full Text] [Related]
22. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Sugimoto Y; Tsukahara S; Oh-hara T; Isoe T; Tsuruo T Cancer Res; 1990 Nov; 50(21):6925-30. PubMed ID: 2170010 [TBL] [Abstract][Full Text] [Related]
24. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Emerson DL; Besterman JM; Brown HR; Evans MG; Leitner PP; Luzzio MJ; Shaffer JE; Sternbach DD; Uehling D; Vuong A Cancer Res; 1995 Feb; 55(3):603-9. PubMed ID: 7834631 [TBL] [Abstract][Full Text] [Related]
25. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo. Huang M; Gao H; Chen Y; Zhu H; Cai Y; Zhang X; Miao Z; Jiang H; Zhang J; Shen H; Lin L; Lu W; Ding J Clin Cancer Res; 2007 Feb; 13(4):1298-307. PubMed ID: 17287296 [TBL] [Abstract][Full Text] [Related]
26. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors. Kuo CC; Liu JF; Chang JY J Pharmacol Exp Ther; 2006 Feb; 316(2):946-54. PubMed ID: 16258022 [TBL] [Abstract][Full Text] [Related]
27. Human DNA topoisomerase I: quantitative analysis of the effects of camptothecin analogs and the benzophenanthridine alkaloids nitidine and 6-ethoxydihydronitidine on DNA topoisomerase I-induced DNA strand breakage. Holden JA; Wall ME; Wani MC; Manikumar G Arch Biochem Biophys; 1999 Oct; 370(1):66-76. PubMed ID: 10496978 [TBL] [Abstract][Full Text] [Related]
28. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Gupta RS; Gupta R; Eng B; Lock RB; Ross WE; Hertzberg RP; Caranfa MJ; Johnson RK Cancer Res; 1988 Nov; 48(22):6404-10. PubMed ID: 2846151 [TBL] [Abstract][Full Text] [Related]
29. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Tsuruo T; Matsuzaki T; Matsushita M; Saito H; Yokokura T Cancer Chemother Pharmacol; 1988; 21(1):71-4. PubMed ID: 3342468 [TBL] [Abstract][Full Text] [Related]
30. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. O'Leary JJ; Shapiro RL; Ren CJ; Chuang N; Cohen HW; Potmesil M Clin Cancer Res; 1999 Jan; 5(1):181-7. PubMed ID: 9918217 [TBL] [Abstract][Full Text] [Related]
31. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Goldenberg GJ; Wang H; Blair GW Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020 [TBL] [Abstract][Full Text] [Related]
32. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Keshelava N; Groshen S; Reynolds CP Cancer Chemother Pharmacol; 2000; 45(1):1-8. PubMed ID: 10647494 [TBL] [Abstract][Full Text] [Related]
33. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Kanzawa F; Sugimoto Y; Minato K; Kasahara K; Bungo M; Nakagawa K; Fujiwara Y; Liu LF; Saijo N Cancer Res; 1990 Sep; 50(18):5919-24. PubMed ID: 2168285 [TBL] [Abstract][Full Text] [Related]
34. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Kaufmann SH Cancer Res; 1991 Feb; 51(4):1129-36. PubMed ID: 1705167 [TBL] [Abstract][Full Text] [Related]
36. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site. Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241 [TBL] [Abstract][Full Text] [Related]
37. Antiangiogenic potential of camptothecin and topotecan. Clements MK; Jones CB; Cumming M; Daoud SS Cancer Chemother Pharmacol; 1999; 44(5):411-6. PubMed ID: 10501915 [TBL] [Abstract][Full Text] [Related]
38. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700 [TBL] [Abstract][Full Text] [Related]
39. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Holm C; Covey JM; Kerrigan D; Pommier Y Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254 [TBL] [Abstract][Full Text] [Related]
40. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells. Traganos F; Kapuscinski J; Gong J; Ardelt B; Darzynkiewicz RJ; Darzynkiewicz Z Cancer Res; 1993 Oct; 53(19):4613-8. PubMed ID: 8402636 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]